for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adaptimmune Therapeutics PLC - ADR

ADAP.OQ

Latest Trade

2.89USD

Change

-0.06(-2.03%)

Volume

264,415

Today's Range

2.86

 - 

2.99

52 Week Range

2.86

 - 

7.34

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.95
Open
2.96
Volume
264,415
3M AVG Volume
18.06
Today's High
2.99
Today's Low
2.86
52 Week High
7.34
52 Week Low
2.86
Shares Out (MIL)
937.22
Market Cap (MIL)
460.80
Forward P/E
-4.20
Dividend (Yield %)
--

Next Event

Q4 2021 Adaptimmune Therapeutics PLC Earnings Release

Latest Developments

More

Adaptimmune Announces Overall Response Rate Of 36% In Its Cancers Clinical Trial

Adaptimmune Enters Into Strategic Collaboration With Genentech

Adaptimmune Reports Second Quarter Financial Results And Business Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adaptimmune Therapeutics PLC - ADR

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer immunotherapy products for people with cancer. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.

Industry

Biotechnology & Drugs

Contact Info

60 Jubilee Avenue

OX14 4RX

United Kingdom

+44.1235.430000

https://www.adaptimmune.com/

Executive Leadership

David M. Mott

Non-Executive Independent Chairman of the Board

Adrian Rawcliffe

Chief Executive Officer, Director

Gavin Hilary James Wood

Chief Financial Officer

William C. Bertrand

Chief Operating Officer

Elliot Norry

Senior Vice President, Chief Medical Officer

Key Stats

2.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.0K

2020

0.0K

2021(E)

0.1K
EPS (USD)

2018

-0.960

2019

-1.320

2020

-0.900

2021(E)

-0.543
Price To Earnings (TTM)
--
Price To Sales (TTM)
73.92
Price To Book (MRQ)
1.91
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-41.20
Return on Equity (TTM)
-37.44

Latest News

Latest News

BRIEF-Adaptimmune Therapeutics PLC Prices Public Offering Of American Depositary Shares

* ADAPTIMMUNE THERAPEUTICS PLC PRICES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

BRIEF-Adaptimmune Proposes Public Offering Of American Depositary Shares

* ADAPTIMMUNE THERAPEUTICS PLC PROPOSES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

BRIEF-Spear T-Cells Targeting Mage-A4 Demonstrate New Responses In Esophagogastric Junction (Egj), Lung, And Head And Neck Cancers

* SPEAR T-CELLS TARGETING MAGE-A4 DEMONSTRATE NEW RESPONSES IN ESOPHAGOGASTRIC JUNCTION (EGJ), LUNG, AND HEAD AND NECK CANCERS – LATE STAGE DEVELOPMENT INITIATED IN EGJ CANCER

BRIEF-Adaptimmune Therapeutics Reports Qtrly Loss Per Share $0.04

* ADAPTIMMUNE THERAPEUTICS PLC SEES AS OF MARCH 31, 2020, ADAPTIMMUNE HAD CASH AND CASH EQUIVALENTS OF $86.4 MILLION

BRIEF-Adaptimmune Therapeutics To Rely On SEC Order To Delay Filing Of Its Quarterly Report On Form 10-Q

* ADAPTIMMUNE THERAPEUTICS PLC - WILL BE RELYING ON SEC ORDER TO DELAY FILING OF ITS QUARTERLY REPORT ON FORM 10-Q FOR THREE MONTHS ENDED MARCH 31, 2020 Source : (https://bit.ly/2xmcdKc) Further company coverage:

BRIEF-EMA Committee for Orphan Medicinal Products adopts positive opinion for Orphan Drug Designation for ADP-A2M4 -Adaptimmune Therapeutics

* POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION FOR ADP-A2M4 IN THE EUROPEAN UNION FOR THE TREATMENT OF SOFT TISSUE SARCOMA FROM EMA' COMMITTEE OF ORPHAN MEDICINAL PRODUCTS Source text for Eikon: Further company coverage:

BRIEF-Adaptimmune Reports Qtrly Loss Per Share $0.05

* ADAPTIMMUNE REPORTS FOURTH QUARTER / FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Adaptimmune Announces Appointment Of Gavin Wood As CFO

* ADAPTIMMUNE ANNOUNCES APPOINTMENT OF GAVIN WOOD AS CHIEF FINANCIAL OFFICER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up